Osteopore (ASX:OSX) subsidiary Osteopore International partnered with Nasdaq-listed CytoMed Therapeutics to develop scaffold-based cellular products for tissue regeneration, according to a Thursday filing with the Australian Securities Exchange.
Under the 18-month deal, CytoMed's mesenchymal stem cells will be combined with Osteopore's bioresorbable scaffolds, with the two companies establishing an advisory committee to assess co-development and resource utilization opportunities, the filing said.
Osteopore shares rose 3% in afternoon trade.
Price (AUD): $0.04, Change: $+0.0010, Percent Change: +2.63%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.